New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Indivior announced findings from two new real-world evidence studies showing that adherence to its monthly injectable buprenorphine, SUBLOCADE, is associated with significantly lower relapse risk and reduced healthcare utilization. The first study, analyzing 3,400 patients, found that those adherent to extended-release buprenorphine were 3.5 to 8.1 times less likely to return to opioid use compared to non-adherent patients or those on other forms of medication-assisted treatment.
Key figures
- Ed visits reduction
- 22%
- Sti visits reduction
- 77%
- Inpatient visits reduction
- 56%
- Outpatient visits reduction
- 21%
- Relapse study patient count
- 3400
- Utilization study oral count
- 120000
- Bacteremia incidence reduction
- 62%
- Utilization study injectable count
- 467
- Relapse risk reduction vs non adherent
- 3.5x to 8.1x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.